Literature DB >> 12180106

Prevention and management of CMV-related problems after hematopoietic stem cell transplantation.

J A Zaia1.   

Abstract

Prevention and management of human cytomegalovirus (CMV) infection after hematopoietic stem cell transplantation has improved substantially in the past decade. However, with this improvement, there is increased complexity in deciding which diagnostic tests, treatment strategies and immunologic assessments are optimal for different patient populations. The purpose of this review is to address certain practical problems that commonly arise and suggest a suitable approach to management that should have wide applicability.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12180106     DOI： 10.1038/sj.bmt.1703407

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


  9 in total

1.  Real-time PCR diagnostics failure caused by nucleotide variability within exon 4 of the human cytomegalovirus major immediate-early gene.

Authors:  Martina Lengerova; Zdenek Racil; Pavlina Volfova; Jana Lochmanova; Jitka Berkovcova; Dana Dvorakova; Jiri Vorlicek; Jiri Mayer
Journal:  J Clin Microbiol       Date:  2007-01-17       Impact factor: 5.948

2.  Pharmacokinetics and safety of intravenous cidofovir for life-threatening viral infections in pediatric hematopoietic stem cell transplant recipients.

Authors:  Amy E Caruso Brown; Mindy N Cohen; Suhong Tong; Rebecca S Braverman; James F Rooney; Roger Giller; Myron J Levin
Journal:  Antimicrob Agents Chemother       Date:  2015-03-02       Impact factor: 5.191

3.  Successful unrelated cord blood transplantation in an infant with Wiskott-Aldrich syndrome following recurrent cytomegalovirus disease.

Authors:  Michiya Kaneko; Tsutomu Watanabe; Hiroyoshi Watanabe; Masahiro Kimura; Hiroko Suzuya; Yasuhiro Okamoto; Ryuji Nakagawa; Yasuhiro Kuroda
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

4.  Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients.

Authors:  Wendi Zhou; Jeff Longmate; Simon F Lacey; Joycelynne M Palmer; Ghislaine Gallez-Hawkins; Lia Thao; Ricardo Spielberger; Ryotaro Nakamura; Stephen J Forman; John A Zaia; Don J Diamond
Journal:  Blood       Date:  2009-04-15       Impact factor: 22.113

5.  Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the inborn errors, infectious diseases and pediatric diseases working parties of EBMT.

Authors:  T Bontant; P Sedlaçek; A Balduzzi; B Gaspar; S Cesaro; H Einsele; C Peters; J-H Dalle
Journal:  Bone Marrow Transplant       Date:  2013-10-28       Impact factor: 5.483

Review 6.  Current translational and clinical practices in hematopoietic cell and gene therapy.

Authors:  David L Digiusto; Hans-Peter Kiem
Journal:  Cytotherapy       Date:  2012-08       Impact factor: 5.414

Review 7.  Molecular diagnosis and management of viral infections in hematopoietic stem cell transplant recipients.

Authors:  Sabine Breuer; Margit Rauch; Susanne Matthes-Martin; Thomas Lion
Journal:  Mol Diagn Ther       Date:  2012-04-01       Impact factor: 4.476

8.  Laboratory-based management of microbiological alerts: effects of an automated system on the surveillance and treatment of nosocomial infections in an oncology hospital.

Authors:  R Passerini; R Biffi; D Riggio; S Pozzi; Mt Sandri
Journal:  Ecancermedicalscience       Date:  2009-03-31

9.  A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector.

Authors:  Z Wang; W Zhou; T Srivastava; C La Rosa; A Mandarino; S J Forman; J A Zaia; W J Britt; D J Diamond
Journal:  Virology       Date:  2008-06-05       Impact factor: 3.616
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.